Ingram M, Buckwalter J G, Jacques D B, Freshwater D B, Abts R M, Techy G B, Miyagi K, Shelden C H, Rand R W, English L W
Experimental and Clinical Immunotherapy Laboratory, Huntington Medical Research Institutes, (HMRI) Pasadena, CA 91101.
Neurol Res. 1990 Dec;12(4):265-73. doi: 10.1080/01616412.1990.11739955.
We present interim survival data for a group of 83 adult patients with recurrent malignant glioma treated by implanting stimulated autologous lymphocytes into the tumour bed following surgical debulking. The patients were treated 6 months or more prior to data analysis. Fifty-nine patients were male and 24 female. The mean age for the entire group was 48.4 years and the mean Karnofsky rating (KR) was 67.2. Eight of the patients had grade II tumours, 33 had grade III tumours and 42 had grade IV tumours. Statistical analysis focuses on tumour grade, KR and patient age, factors that have been shown to affect survival in previous studies. Multifactorial analyses are employed to identify interrelationships among factors related to survival. Seven patients (8%) did not respond to immunotherapy, 76 (92%) had a good initial response. Twenty-five patients (30.1%) are living and 18 (22%) have shown no evidence of recurrence. Results are evaluated in the light of those obtained in trials of other experimental therapies for recurrent malignant gliomas. It is concluded that the present protocol offers a safe and comparatively effective treatment option.
我们提供了一组83例复发性恶性胶质瘤成年患者的中期生存数据，这些患者在手术切除肿瘤后，将经刺激的自体淋巴细胞植入瘤床进行治疗。这些患者在数据分析前6个月或更长时间接受了治疗。59例为男性，24例为女性。整个组的平均年龄为48.4岁，平均卡氏评分（KR）为67.2。其中8例患者为II级肿瘤，33例为III级肿瘤，42例为IV级肿瘤。统计分析聚焦于肿瘤分级、KR和患者年龄，这些因素在以往研究中已被证明会影响生存。采用多因素分析来确定与生存相关因素之间的相互关系。7例患者（8%）对免疫治疗无反应，76例（92%）有良好的初始反应。25例患者（30.1%）仍存活，18例（22%）未显示复发迹象。根据复发性恶性胶质瘤其他实验性治疗试验所获得的结果对本研究结果进行评估。得出的结论是，本方案提供了一种安全且相对有效的治疗选择。
